BR112023023726A2 - Compostos heterocíclicos substituídos - Google Patents

Compostos heterocíclicos substituídos

Info

Publication number
BR112023023726A2
BR112023023726A2 BR112023023726A BR112023023726A BR112023023726A2 BR 112023023726 A2 BR112023023726 A2 BR 112023023726A2 BR 112023023726 A BR112023023726 A BR 112023023726A BR 112023023726 A BR112023023726 A BR 112023023726A BR 112023023726 A2 BR112023023726 A2 BR 112023023726A2
Authority
BR
Brazil
Prior art keywords
substituted heterocyclic
heterocyclic compounds
compounds
useful
tyk
Prior art date
Application number
BR112023023726A
Other languages
English (en)
Portuguese (pt)
Inventor
Edward Mertzman Michael
M Moslin Ryan
H Spergel Steven
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112023023726A2 publication Critical patent/BR112023023726A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112023023726A 2021-05-14 2022-05-13 Compostos heterocíclicos substituídos BR112023023726A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188498P 2021-05-14 2021-05-14
US202263318508P 2022-03-10 2022-03-10
PCT/US2022/029117 WO2022241174A1 (en) 2021-05-14 2022-05-13 Substituted heterocyclic compounds

Publications (1)

Publication Number Publication Date
BR112023023726A2 true BR112023023726A2 (pt) 2024-01-30

Family

ID=81927791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023726A BR112023023726A2 (pt) 2021-05-14 2022-05-13 Compostos heterocíclicos substituídos

Country Status (12)

Country Link
US (2) US11884650B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337648B1 (cg-RX-API-DMAC7.html)
JP (1) JP7818623B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240008338A (cg-RX-API-DMAC7.html)
AU (1) AU2022272725A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023726A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218579A1 (cg-RX-API-DMAC7.html)
ES (1) ES3059456T3 (cg-RX-API-DMAC7.html)
IL (1) IL308422A (cg-RX-API-DMAC7.html)
MX (1) MX2023013351A (cg-RX-API-DMAC7.html)
TW (1) TW202311248A (cg-RX-API-DMAC7.html)
WO (1) WO2022241174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122520625A (zh) 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
EP4337650A1 (en) * 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240007242A (ko) * 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
CN118812511A (zh) * 2023-04-21 2024-10-22 浙江文达医药科技有限公司 作为tyk2抑制剂的杂环化合物及合成和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
KR102858043B1 (ko) * 2018-10-30 2025-09-10 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
US20230295119A1 (en) 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
EP4337650A1 (en) 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240317718A1 (en) 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240007242A (ko) 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물

Also Published As

Publication number Publication date
US20240124421A1 (en) 2024-04-18
EP4337648A1 (en) 2024-03-20
US20220388987A1 (en) 2022-12-08
US11884650B2 (en) 2024-01-30
JP2024518555A (ja) 2024-05-01
TW202311248A (zh) 2023-03-16
JP7818623B2 (ja) 2026-02-20
CA3218579A1 (en) 2022-11-17
MX2023013351A (es) 2023-11-27
IL308422A (en) 2024-01-01
KR20240008338A (ko) 2024-01-18
WO2022241174A1 (en) 2022-11-17
EP4337648B1 (en) 2025-12-24
AU2022272725A1 (en) 2024-01-04
ES3059456T3 (en) 2026-03-20

Similar Documents

Publication Publication Date Title
MX2023013445A (es) Compuestos heterociclicos sustituidos.
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
BR112022020291A2 (pt) Inibidores de cd38
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
MX2023013351A (es) Compuestos heterociclicos sustituidos.
BR112022024156A2 (pt) Compostos heterocílicos antelmínticos
BR112015022575A2 (pt) composto de fórmula, pró-droga de um composto, kit, métodos para regular uma trajetória, para regular qualquer uma ou mais dentre enzimas, para reduzir metabólitos, para alterar níveis de triptofano, para tratar supressão imunológica, para reduzir ou eliminar um distúrbio imunomediado, para inibir a ativação de enzimas, para tratar uma doença, para inibir uma produção de anticorpo autoimune, para preparar um composto e para diagnosticar e tratar uma doença e composto obtenível por um método
BR112022006507A2 (pt) Compostos heterocíclicos de arilmetileno como bloqueadores de canais de agitador de potássio kv1.3
SA520411783B1 (ar) مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات جاما لـ pi3k-
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BR112015026410A2 (pt) derivados de dolastatina 10 e auristatinas
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
EA202090068A1 (ru) Соединения, влияющие на синтез пигмента и их применение для лечения бактериальных заболеваний
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
BR112021011325A2 (pt) Derivados de rapamicina
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
BR112021019817A2 (pt) Compostos de pirrol
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
EA202091804A1 (ru) Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
BR112021024300A2 (pt) Formas de sais cristalinas de um inibidor de quinase
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112022008223A2 (pt) Métodos de tratamento e/ou prevenção de eventos cardiovasculares adversos maiores (ecam) com uma combinação de um inibidor do bromodomínio bet e um inibidor da proteína de transporte de glicose dependente de sódio 2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]